Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination
AstraZeneca & Chi-Med: Harnessing the potential of Chinese science innovation
An IMED Collaboration Update
The early seeds of AstraZeneca’s collaboration with Hutchison MediPharma in China were sown by our scientists in Shanghai, through their relationships within the local scientific community. An early exchange of ideas and a Hutchison presentation of its early pipeline prompted our interest in a novel oncology compound – a potent ATP-competitive c-Met inhibitor. In December 2011, we signed a global licensing, co-development and commercialisation agreement for the compound. It is being developed as an oral drug for treatment of solid tumours. Six clinical studies are currently running across several countries, with clinical activity observed in kidney, lung, stomach and colon cancers.Download collaboration update (PDF 340kb)
All Directors are collectively responsible for the success of AstraZeneca. Discover general information, images and biographies of our Board of Directors.
AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.
Path to new medicines
The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.
Visit our dedicated neuroscience site for more information on our research and partnering in the area.
Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines